BioSpace News Archive

Business

Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim

Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects

October 1, 2019
·
2 min read
FDA

Janssen’s Invokana Becomes First Drug Approved in 20 Years to Slow Diabetic Kidney Disease

Janssen’s Invokana snagged another regulatory approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.

October 1, 2019
·
3 min read
·
Alex Keown
Three Retail Pharmacies Suspend Sales of Sanofi’s Zantac

In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, three major drug store retailers in the United States have removed the antacid product from the shelves.

October 1, 2019
·
2 min read
·
Alex Keown
Business

Creoptix Closes Successful Series C Financing Round to Support Further Growth

Creoptix AG announced that is has raised CHF 8 million in the first closing as part of a Series C financing round.

October 1, 2019
·
3 min read
Business

Nordic Nanovector Appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs

Nordic Nanovector ASA announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs.

October 1, 2019
·
4 min read
Business

Erika Söderberg Johnson Leaves Biotage

Erika Söderberg Johnson has informed Biotage that she, after eight years of employment, is leaving the position as CFO.

October 1, 2019
·
1 min read
Policy

Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon

Calliditas Therapeutics AB announced that the European Medicines Agency has provided positive guidance related to a conditional marketing authorization of the company’s lead compound Nefecon, currently in Phase 3 clinical trials in IgA nephropathy.

October 1, 2019
·
3 min read
Drug Development

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma B.V., a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury with its innovative recombinant human Alkaline Phosphatase therapeutic announces that it has expanded its senior team with two appointments.

October 1, 2019
·
7 min read
Business

Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Numab Therapeutics AG announced the initiation of a partnership with Eisai, Co., Ltd, under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform.

October 1, 2019
·
3 min read
Senefill, Novasep’s Commercial Facility for Aseptic Filling and Finishing Operations, Is Now Ready to Operate

Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging

October 1, 2019
·
2 min read